New Targeted Drug sac-TMT Improves Survival in Advanced Endometrial Cancer

A new targeted cancer drug called sac-TMT is showing promising results for patients with advanced or recurrent endometrial cancer. In a major Phase 3 clinical trial, the treatment improved both overall survival and progression-free survival compared with standard chemotherapy after previous treatments stopped working. In this episode, we break down the latest TroFuse-005 trial results, how antibody-drug conjugates work, and why this development could change future treatment options for advanc...